Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody–radionuclide conjugate 177lu-lilotomab satetraxetan. Blakkisrud, J., Holtedahl, J. E., Løndalen, A., Dahle, J., Bach-Gansmo, T., Holte, H., Nygaard, S., Kolstad, A., & Stokke, C. Journal of Nuclear Medicine, 59(4):704–710, Soc Nuclear Med, 2018.
doi  bibtex   
@article{blakkisrud2018biodistribution,
  title={Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody--radionuclide conjugate 177lu-lilotomab satetraxetan},
  author={Blakkisrud, Johan and Holtedahl, Jon Erik and L{ø}ndalen, Ayca and Dahle, Jostein and Bach-Gansmo, Tore and Holte, Harald and Nygaard, Stine and Kolstad, Arne and Stokke, Caroline},
  journal={Journal of Nuclear Medicine},
  volume={59},
  number={4},
  pages={704--710},
  year={2018},
  publisher={Soc Nuclear Med},
  doi={10.2967/jnumed.117.195347}
}

Downloads: 0